Committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.
Phone: +1 484-801-4670
Total raised: $21M
Investors 6
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Avoro Capi... | avorocapit... |
| - | Sofinnova ... | sofinnova.... |
| - | Canaan Par... | canaan.com |
| - | Bain Capit... | baincapita... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.01.2013 | Series C | $21M | - |
Mentions in press and media 22
| Date | Title | Description |
| 11.02.2025 | Immedica completes acquisition of Marinus Pharmaceuticals, Inc. | Immedica completes acquisition of Marinus Pharmaceuticals, Inc. Tue, Feb 11, 2025 14:35 CET Report this content Stockholm, Sweden – February 11, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today ... |
| 07.02.2025 | Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. | Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. Fri, Feb 07, 2025 12:35 CET Report this content Stockholm, Sweden – February 7, 2025 – Immedica Pharma AB (“Immedica”),... |
| 09.01.2025 | Highway to Investment: KKR and OTPP Drive into India's Infrastructure | In the bustling world of finance, highways are more than just asphalt and concrete. They are lifelines, connecting cities, economies, and opportunities. Recently, two titans of investment, KKR and the Ontario Teachers’ Pension Plan (OTPP), ... |
| 08.01.2025 | Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. | Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. Wed, Jan 08, 2025 22:05 CET Report this content Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading g... |
| 30.12.2024 | Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. | Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. Mon, Dec 30, 2024 13:00 CET Report this content Stockholm, Sweden and Radnor, Pa. – December 30, 2024 - Immedica Pharma AB (Immedica), a leading global rare disease... |
| 15.10.2024 | Датская компания Lundbeck приобретает американского разработчика лекарства от эпилепсии за $2,6 млрд | Сделка расширяет портфель услуг копенгагенской компании Lundbeck по лечению неврологических заболеваний, таких как болезнь Паркинсона, мигрень и болезнь Альцгеймера. Lundbeck прогнозирует потенциальный мировой пик продаж в размере $1,5–2 мл... |
| 13.10.2024 | Navigating the Micro-Cap Maze: Opportunities and Pitfalls in the Stock Market | Micro-cap stocks are like hidden gems in a vast ocean. They can shine brightly or sink without a trace. Investors are drawn to their potential for explosive growth, but the risks are as real as the rewards. This article explores three micro... |
| 11.10.2024 | 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success. | Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory. Others are companies that may have yet to generate any substantial revenues but could... |
| 14.08.2024 | The Benefits of Genetic Testing for Patients with CDKL5 Deficiency Disorder and Other Rare Genetic Epilepsies | (BPT) - CDKL5 deficiency disorder, one of the most common genetic epilepsies, is estimated to occur in approximately 100 newborns in the U.S. per year. CDKL5 deficiency disorder, or CDD, is a rare, X-linked developmental and epileptic encep... |
| 03.08.2024 | MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law Firm | NEW YORK, Aug. 3, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (th... |
Show more